Form 483 · FEI 3016774658

Form 483 issued November 8, 2024 · Clarence, New York

Inspection
Nov 4 – Nov 8, 2024
Observations
9
Pages
9
FEI number
3016774658

In short: On November 8, 2024, FDA issued a Form 483 with 9 observations to an FDA-inspected site in Clarence, New York (FEI 3016774658) after an inspection that ran Nov 4 – Nov 8, 2024. The investigators were Kara J. Wright, Lauren H. Augustyniak and Vivin George. Most observations concern quality system and laboratory controls.

At a glance

Observations span 4 systems, led by quality system.

Quality system2
Laboratory controls2
Production2
Facilities & equipment2
Other1

What FDA observed

Preview: the opening words of each observation
  1. 01

    There is no quality…

  2. 02

    Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory…

  3. 03

    Drug product component testing is deficient in that at least one specific test to verify the…

  4. 04

    An adequate number of batches of each drug product are not tested to determine…

5 more observations

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at an FDA-inspected site?

FDA listed 9 observations on this Form 483, mostly about quality system, laboratory controls and production. The opening words of each observation are shown on this page.

Who inspected an FDA-inspected site?

Kara J. Wright, Lauren H. Augustyniak and Vivin George are named on this Form 483, for the inspection of Nov 4 – Nov 8, 2024. Each investigator has a profile showing what they cite most.

When was an FDA-inspected site inspected by FDA?

The inspection ran Nov 4 – Nov 8, 2024, and the Form 483 is dated November 8, 2024.

How do I get the full Form 483 for an FDA-inspected site?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free